Eric Benevich
Chief Commercial Officer; Director · 3 filings · Latest: May 11, 2026
aTYR PHARMA INC
NEUROCRINE BIOSCIENCES INC
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
NBIX | Eric Benevich | Chief Commercial Officer | Feb 13, 2026 | Option Exercise | $0.00 | 4,044 | — | 56,664 | |
NBIX | Eric Benevich | Chief Commercial Officer | Feb 12, 2026 | Option Exercise | $0.00 | 2,005 | — | 54,760 | |
NBIX | Eric Benevich | Chief Commercial Officer | Jan 31, 2026 | Option Exercise | $0.00 | 2,294 | — | 54,047 | |
NBIX | ERIC BENEVICH | — | Nov 28, 2025 | Proposed Sale | $151.58 | 5,970 | $904.9K | — | |
NBIX | ERIC S BENEVICH | — | Feb 13, 2025 | Proposed Sale | $117.18 | 1,056 | $123.7K | — | |
NBIX | ERIC BENEVICH | — | Feb 13, 2025 | Proposed Sale | $117.18 | 1,098 | $128.7K | — | |
NBIX | ERIC BENEVICH | — | Feb 10, 2025 | Proposed Sale | $122.62 | 980 | $120.2K | — | |
NBIX | ERIC BENEVICH | — | Jan 31, 2025 | Proposed Sale | $153.29 | 1,207 | $185.0K | — |